CEO: Mary Kerr

Advent Contact: Kaasim Mahmood

Breakthrough treatment for chronic debilitating Women’s Health conditions

KaNDy Therapeutics is a UK based clinical-stage company focused on optimizing the potential of NT-814 as a breakthrough medicine for the treatment of chronic debilitating Women’s Health conditions. NT-814 is a first-in-class, once daily, dual mechanism neurokinin-1,3 receptor antagonist. The medicine is being developed as a non-hormonal alternative to hormone replacement therapy for the treatment of postmenopausal symptoms (PMS). NT-814 has been spun out of NeRRe Therapeutics Holdings Ltd into KaNDy Therapeutics Ltd, a separate legal entity. The new company will advance the development of NT-814 into Phase 2b in the lead indication PMS while also exploring its potential in other Women's Health indications. All formulation, pre-clinical and clinical safety and efficacy data, and intellectual property associated with NT-814 have been transferred to the new company.


KaNDy Therapeutics Announces Positive Phase 2b Data in Post-Menopausal Women with its Lead Non-Hormonal Product NT-814

Advent Life Sciences announces sale of its portfolio Company KaNDy Therapeutics to Bayer AG for USD 425M upfront plus USD 450M in potential development milestones followed by further potential commercial milestones.